NPPB and chronic thromboembolic pulmonary hypertension: Another highly cited study found similar results in patients with CTEPH, finding that riociguat improved the 6-min walk test, decreased pulmonary vascular resistance and NT-proBNP levels, and improved life quality in patients with CTEPH.